Livzon Pharmaceutical
Livzon Pharmaceutical Group Inc., commonly referred to as Livzon, is a prominent player in the pharmaceutical industry, headquartered in China (CN). Founded in 1992, the company has established a strong presence in various operational regions, focusing on the development, manufacturing, and marketing of innovative pharmaceutical products. Specialising in areas such as biopharmaceuticals, traditional Chinese medicine, and chemical pharmaceuticals, Livzon is recognised for its commitment to quality and research-driven solutions. The company’s core offerings include a range of therapeutic agents, particularly in the fields of oncology and infectious diseases, which distinguish it in a competitive market. With a robust market position, Livzon has achieved significant milestones, including numerous product approvals and collaborations that enhance its global footprint. The company continues to advance its mission of improving health outcomes through innovative therapies and a dedication to excellence in pharmaceutical development.
DitchCarbon Score
How does Livzon Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Livzon Pharmaceutical's score of 48 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Livzon Pharmaceutical's reported carbon emissions
In 2024, Livzon Pharmaceutical, headquartered in China (CN), reported total carbon emissions of approximately 521,159,370 kg CO2e. This figure includes 194,440,580 kg CO2e from Scope 1 emissions, 326,718,790 kg CO2e from Scope 2 emissions, and a significant 1,709,496,180 kg CO2e from Scope 3 emissions. The total emissions for 2023 were about 514,332,930 kg CO2e, with Scope 1 at 155,807,280 kg CO2e and Scope 2 at 358,525,650 kg CO2e. Livzon has set ambitious climate commitments, aiming for net-zero emissions by 2050, with a starting year of 2023. In the near term, the company targets a 22% reduction in emissions per RMB 10,000 of output value for both Scope 1 and Scope 2 by 2024, compared to 2020 levels. Additionally, they aim for a 26% reduction in the same metric by 2025. The emissions data is sourced directly from Livzon Pharmaceutical Group Inc., with no cascading from a parent company. The company is actively working towards its climate goals, reflecting a commitment to sustainability in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 30,427,790 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 543,952,460 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Livzon Pharmaceutical is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
